Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Theoretically, coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of topical tacrolimus. The proposed mechanism involves inhibition of CYP450 3A4-mediated metabolism of tacrolimus, which is primary metabolized by this isoenzyme. However, systemic exposure from topical tacrolimus is reported to be minimal (less than 1 ng/mL) and so clinically significant drug interactions are not expected. Nevertheless, the possibility of an interaction cannot be ruled out.

MANAGEMENT: According to the manufacturer, caution is advised if topical tacrolimus is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for systemic tacrolimus adverse effects including immunosuppression, infection, hyperkalemia, malignancy, nephrotoxicity, neurotoxicity, and hypertension.

Stiripentol should be taken during a meal to help with its absorption; however, it should not be taken with milk, dairy products (e.G., yogurt, soft cream cheese), fruit juice, or carbonated (fizzy) beverages. Also avoid or limit the use of alcohol because it can increase side effects of stiripentol such as dizziness and drowsiness. Patients should not engage in activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them. Food and beverages that may contain caffeine or theophylline such as colas, chocolate, coffee, tea, or energy drinks should also be avoided, since stiripentol may affect the clearance of these substances from the body. Some medications may also contain caffeine, so check product labels to verify the ingredients before taking, or ask a pharmacist or other healthcare provider for assistance. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.